News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen: Top Start Ups to Watch
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Insights
Jobs
Career Advice
Companies
Hotbeds
More
Best Places to Work
Employer Resources
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen: Top Start Ups to Watch
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Insights
Jobs
Career Advice
Companies
Hotbeds
More
Best Places to Work
Employer Resources
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Search Query
Submit Search
Search Results
Submit
Looking for jobs?
Search jobs
Close
175,753 Results
Type
Article (29913)
Company Profile (28)
Press Release (145812)
Section
Business (46702)
Career Advice (1744)
Deals (9543)
Drug Delivery (115)
Drug Development (30128)
Employer Resources (190)
FDA (6248)
Job Trends (5464)
News (92354)
Policy (12342)
Tag
Academia (1561)
Alliances (12815)
Alzheimer's disease (701)
Antibody-drug conjugate (ADC) (77)
Approvals (6161)
Artificial intelligence (83)
Bankruptcy (110)
Best Places to Work (4216)
Biosimilars (72)
Breast cancer (59)
Cancer (493)
Cardiovascular disease (66)
Career advice (1460)
CAR-T (58)
Cell therapy (128)
Clinical research (22825)
Collaboration (165)
COVID-19 (2221)
Data (371)
Diabetes (96)
Diagnostics (1986)
Diversity, equity & inclusion (47)
Drug pricing (99)
Earnings (15766)
Employer resources (163)
Events (21600)
Executive appointments (77)
FDA (6398)
Funding (128)
Gene therapy (133)
GLP-1 (583)
Government (3174)
Healthcare (6177)
Infectious disease (2278)
Inflammatory bowel disease (75)
Interviews (346)
IPO (3822)
Job creations (1321)
Job search strategy (1186)
Layoffs (443)
Legal (2411)
Lung cancer (98)
Management (64)
Manufacturing (101)
Medical device (3729)
Medtech (3730)
Mergers & acquisitions (5726)
Metabolic disorders (334)
Neuroscience (871)
NextGen Class of 2024 (2425)
Non-profit (1959)
Northern California (426)
Obesity (220)
Opinion (208)
Patents (56)
People (13105)
Phase I (6399)
Phase II (9789)
Phase III (9361)
Pipeline (192)
Podcasts (90)
Policy (89)
Postmarket research (966)
Preclinical (2375)
Radiopharmaceuticals (67)
Rare diseases (144)
Real estate (1577)
Recruiting (72)
Regulatory (7671)
Research institute (1222)
Resumes & cover letters (275)
Southern California (352)
Startups (1299)
The Weekly (56)
United States (3497)
Vaccines (570)
Weight loss (209)
Date
Today (41)
Last 7 days (215)
Last 30 days (1086)
Last 365 days (11066)
2024 (10116)
2023 (12185)
2022 (16043)
2021 (17100)
2020 (16646)
2019 (15489)
2018 (12602)
2017 (8993)
2016 (8343)
2015 (9070)
2014 (6373)
2013 (4956)
2012 (5197)
2011 (5415)
2010 (4856)
Location
Africa (426)
Asia (10574)
Australia (1990)
California (926)
Canada (335)
China (78)
Connecticut (59)
Europe (27715)
Florida (100)
Illinois (99)
Indiana (74)
Maryland (212)
Massachusetts (650)
New Jersey (286)
New York (276)
North Carolina (154)
Northern California (426)
Ohio (46)
Pennsylvania (161)
South America (489)
Southern California (352)
Texas (109)
Washington State (91)
175,753 Results for "motus gi".
Filters
Sort By
Relevance
Relevance
Newest
Oldest
Business
Motus GI Reports First Quarter 2024 Financial Results and Provides Corporate Update
Motus GI Holdings, Inc. reported its financial results for the first quarter ended March 31, 2024, and provided a corporate update.
May 14, 2024
·
7 min read
Business
Motus GI Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Corporate Update
Motus GI Holdings, Inc., (NASDAQ: MOTS) (“Motus GI” or the “Company”), a medical technology company focused on improving endoscopic outcomes and experiences, today reported its financial results for the fourth quarter and year ended December 31, 2023, and provided a corporate update.
March 18, 2024
·
9 min read
Motus GI Holdings Granted a U.S. Patent for a Key Feature Embodied by the Pure-Vu® System to Avoid Clogging in Cleansing the GI Tract
Motus GI Holdings, Inc. today announced that the United States Patent and Trademark Office (USPTO) has issued the Company a new patent (patent # 11904085) titled, “Colon Cleaning System with Automatic Self-Purging Feature.”
February 21, 2024
·
3 min read
Deals
Motus GI Holdings, Inc. Announces Exercise of Warrants for $2.7 Million Gross Proceeds
Motus GI Holdings, Inc. today announced that it has entered into a definitive agreement for the immediate exercise of an outstanding Series B common stock purchase warrant held by an institutional investor to purchase an aggregate of 2,933,334 shares of the Company’s common stock.
February 22, 2024
·
4 min read
Motus GI Announces First Upper GI Patient Procedure for FDA Cleared Pure-Vu® EVS Gastro
Motus GI Holdings, Inc. (NASDAQ: MOTS) (“Motus GI” or the “Company”), a medical technology company focused on improving endoscopic outcomes and experiences, announced today that the Pure-Vu® EVS Gastro was successfully used in the first procedure since receiving FDA clearance.
November 10, 2023
·
4 min read
BioMidwest
Motus GI Holdings, Inc. Announces Adjournment of the February 16, 2024 Special Meeting of Stockholders
Motus GI Holdings, Inc., announced that its special meeting of stockholders held on February 16, 2024 was convened and then adjourned, without conducting any business, in order to provide stockholders additional time within which to vote on the proposal described in the Company’s definitive proxy statement filed with the Securities and Exchange Commission on January 24, 2024.
February 16, 2024
·
3 min read
Business
Motus GI Reports Third Quarter 2023 Financial Results and Provides Corporate Update
Motus GI Holdings, Inc., (NASDAQ: MOTS) (“Motus GI” or the “Company”), a medical technology company focused on improving endoscopic outcomes and experiences, today reported its financial results for the third quarter ended September 30, 2023, and provided a corporate update.
November 13, 2023
·
8 min read
BioMidwest
Motus GI Amends Royalty Agreement
Motus GI Holdings, Inc. announced it has reached an agreement to amend the royalty payment rights and, subsequently, cancelled the royalty rights in exchange for an aggregate of 1,455,641 shares of Motus common stock, effective as of September 12, 2023.
September 14, 2023
·
3 min read
FDA
Motus GI Receives FDA Clearance to Commercialize Pure-Vu EVS Gastro and Gen 4 Colon
Motus GI Holdings, Inc., (NASDAQ: MOTS) (“Motus GI” or the “Company”), a medical technology company focused on improving endoscopic outcomes and experiences, announced today that it has received clearance from the U.S. Food and Drug Administration (“FDA”) for the special 510(k) for technological advancements featured in the new Pure-Vu EVS Gastro and Gen 4 Colon system.
October 24, 2023
·
4 min read
BioMidwest
Motus GI Holdings, Inc. Announces Pricing of $5.0 Million Public Offering
Motus GI Holdings, Inc. announced the pricing of a public offering of 3,333,334 shares of common stock, Series A common warrants to purchase up to 3,333,334 shares of common stock, and Series B common warrants to purchase up to 3,333,334 shares of common stock, at a combined public offering price of $1.50 per share and Series A common warrant and Series B common warrant.
December 18, 2023
·
4 min read
1 of 17,576
Next